Driven to metastasize: Kinases as potential therapeutic targets in prostate cancer.
作者信息
Feng Felix Y, Kothari Vishal
机构信息
Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, MI 48109; Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109; Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109
Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, MI 48109;
出版信息
Proc Natl Acad Sci U S A. 2016 Jan 19;113(3):473-5. doi: 10.1073/pnas.1522938113. Epub 2016 Jan 8.
Abstract
摘要
相似文献
1
Driven to metastasize: Kinases as potential therapeutic targets in prostate cancer.促使转移：激酶作为前列腺癌潜在的治疗靶点
Proc Natl Acad Sci U S A. 2016 Jan 19;113(3):473-5. doi: 10.1073/pnas.1522938113. Epub 2016 Jan 8.
2
Prostate cancer: A walk on the wild side - wild-type kinases promote metastasis.前列腺癌：狂野边缘之行——野生型激酶促进转移。
Nat Rev Urol. 2016 Feb;13(2):63. doi: 10.1038/nrurol.2015.300. Epub 2015 Dec 22.
3
Functional screen identifies kinases driving prostate cancer visceral and bone metastasis.功能筛选鉴定出驱动前列腺癌内脏和骨转移的激酶。
Proc Natl Acad Sci U S A. 2016 Jan 12;113(2):E172-81. doi: 10.1073/pnas.1521674112. Epub 2015 Nov 30.
4
Visceral metastases in prostate cancer: an underestimated and understudied subgroup.前列腺癌的内脏转移：一个被低估且研究不足的亚组。
Oncology (Williston Park). 2014 Nov;28(11):980-6.
5
Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer.转移部位对转移性前列腺癌患者生存的影响。
Eur Urol. 2015 Aug;68(2):325-34. doi: 10.1016/j.eururo.2014.07.020. Epub 2014 Aug 6.
6
Prostate cancer: Better use of bone scans in prostate cancer.前列腺癌：更好地利用骨扫描诊断前列腺癌。
Nat Rev Urol. 2015 Apr;12(4):190-1. doi: 10.1038/nrurol.2014.305. Epub 2014 Nov 11.
7
Biology of Bone Metastases in Prostate Cancer.前列腺癌骨转移的生物学
Urology. 2016 Jun;92:6-13. doi: 10.1016/j.urology.2015.12.039. Epub 2016 Jan 6.
8
Cellular interactions in the tropism of prostate cancer to bone.前列腺癌骨转移中的细胞相互作用。
Int J Cancer. 2004 Jul 1;110(4):497-503. doi: 10.1002/ijc.20153.
9
[Bone metastasis from prostate cancer].[前列腺癌骨转移]
Clin Calcium. 2014 Aug;24(8):1169-75.
10
Pathogenesis of osteoblastic bone metastases from prostate cancer.前列腺癌成骨性骨转移的发病机制。
Cancer. 2010 Mar 15;116(6):1406-18. doi: 10.1002/cncr.24896.
引用本文的文献
1
The Role of Alcohol-Induced Golgi Fragmentation for Androgen Receptor Signaling in Prostate Cancer.酒精诱导的高尔基片段化在前列腺癌雄激素受体信号转导中的作用。
Mol Cancer Res. 2019 Jan;17(1):225-237. doi: 10.1158/1541-7786.MCR-18-0577. Epub 2018 Sep 17.
2
Inhibition of KPNA4 attenuates prostate cancer metastasis.抑制核转运蛋白α4可减轻前列腺癌转移。
Oncogene. 2017 May 18;36(20):2868-2878. doi: 10.1038/onc.2016.440. Epub 2016 Dec 12.
本文引用的文献
1
Functional screen identifies kinases driving prostate cancer visceral and bone metastasis.功能筛选鉴定出驱动前列腺癌内脏和骨转移的激酶。
Proc Natl Acad Sci U S A. 2016 Jan 12;113(2):E172-81. doi: 10.1073/pnas.1521674112. Epub 2015 Nov 30.
2
Integrative clinical genomics of advanced prostate cancer.晚期前列腺癌的整合临床基因组学
Cell. 2015 May 21;161(5):1215-1228. doi: 10.1016/j.cell.2015.05.001.
3
Enzalutamide in metastatic prostate cancer before chemotherapy.恩杂鲁胺治疗化疗前转移性前列腺癌。
N Engl J Med. 2014 Jul 31;371(5):424-33. doi: 10.1056/NEJMoa1405095. Epub 2014 Jun 1.
4
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.多西他赛和达沙替尼或安慰剂治疗转移性去势抵抗性前列腺癌男性患者（READY）：一项随机、双盲、III 期临床试验。
Lancet Oncol. 2013 Dec;14(13):1307-16. doi: 10.1016/S1470-2045(13)70479-0. Epub 2013 Nov 8.
5
The mutational landscape of lethal castration-resistant prostate cancer.致命性去势抵抗性前列腺癌的突变全景。
Nature. 2012 Jul 12;487(7406):239-43. doi: 10.1038/nature11125.
6
A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer.一项索拉非尼联合比卡鲁胺治疗化疗初治去势抵抗性前列腺癌患者的 II 期研究。
Invest New Drugs. 2012 Aug;30(4):1652-9. doi: 10.1007/s10637-011-9722-5. Epub 2011 Jul 23.
7
Targeting anaplastic lymphoma kinase in lung cancer.针对肺癌中的间变性淋巴瘤激酶。
Clin Cancer Res. 2011 Apr 15;17(8):2081-6. doi: 10.1158/1078-0432.CCR-10-1591. Epub 2011 Feb 2.
8
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.多西他赛治疗后进展的转移性去势抵抗性前列腺癌患者中，泼尼松联合卡巴他赛或米托蒽醌治疗的随机开放标签试验。
Lancet. 2010 Oct 2;376(9747):1147-54. doi: 10.1016/S0140-6736(10)61389-X.
9
Inhibition of mutated, activated BRAF in metastatic melanoma.转移性黑色素瘤中突变激活 BRAF 的抑制。
N Engl J Med. 2010 Aug 26;363(9):809-19. doi: 10.1056/NEJMoa1002011.
10
Integrative genomic profiling of human prostate cancer.人类前列腺癌的综合基因组分析。
Cancer Cell. 2010 Jul 13;18(1):11-22. doi: 10.1016/j.ccr.2010.05.026. Epub 2010 Jun 24.
Zotero 插件